You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復星醫藥(02196.HK)2020年純利升10.27%至36.63億元 過億單品達39個
格隆匯 03-30 00:44

格隆匯3月30日丨復星醫藥(02196.HK)公佈2020年度業績,期內集團實現營業收入301.63億元,同比增長6.25%;歸屬於上市公司股東淨利潤36.63億元,同比增長10.27%;歸屬於上市公司股東的扣除非經常性損益的淨利潤27.18億元,同比增長21.65%;經營活動產生的現金流量淨額25.80億元,剔除2020年末向BioNTech支付1.25億歐元mRNA新冠疫苗首付款影響後,同口徑增長11.19%;每股基本盈利1.43元,宣派末期股息每股0.43元。

報吿期內,集團繼續加大研發投入,全年研發投入共計40.03億元,同比增長15.59%;其中,研發費用為27.95億元,同比增加7.54億元,增長36.94%。

報吿期內,集團製藥業務實現營業收入217.48億元,同比增長0.64%;實現分部業績22.62億元,同比增長17.51%;分部利潤23.55億元,同比增長13.60%。製藥業務研發投入為36.70億元,同比增長17.21%,製藥業務研發投入佔製藥業務收入的16.77%;其中,研發費用為24.68億元,同比增加7.27億元,增長41.76%,佔製藥業務收入的11.28%。

2020年,集團製藥板塊銷售額過億的製劑單品或系列共39個,較去年同口徑淨增加3個。

2021年,集團將繼續加快產品臨牀推進、提升註冊進度,計劃在境外開展的臨牀試驗項目將達到10餘項,其中自主研發的FCN-159將進入國際多中心臨牀試驗階段。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account